Merck (NYSE:MRK) announced today that it entered into an agreement to supply the U.S. government with its molnupiravir (MK-4482) for treating COVID-19.
Molnupiravir, developed through a collaboration between Merck and Ridgeback Biotherapeutics, is currently under evaluation in a Phase 3 clinical trial for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 infection and at least one risk factor associated with poor disease outcomes.
Get the full story at our sister site, Pharmaceutical Processing World.